Novavax Submits Final Data to Seek the US FDA’s EUA for its COVID-19 Vaccine
Shots:
- The company has submitted the chemistry, manufacturing and controls (CMC) data module, completing the final data packages required for the EUA application of NVX-CoV2373 with Matrix-M adjuvant
- Novavax is all set to file an application with the US FDA in 30 days, seeking EUA for its vaccine, as per the FDA guidance for all EUA applications for vaccines
- The company plans to later supplement the submission, with data from additional manufacturing sites across its global supply chain
Ref: Novavax | Image: Medpage Today
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com